Fundraising Fox

Genpulse

1 known investors

Genpulse builds AI infrastructure and purpose-built devices that capture health data and process it in real time to deliver insights to users and practitioners. It offers medical-grade AI diagnostic devices (for hair/scalp, skin, dental, eye, and gynecological analysis), white-label deployment, and APIs, SDKs, and medical AI datasets for building healthcare applications.

Also known as Genpulse Β· GENPULSE

Investors Β· 1

Company profile

researched Aug 2026

Genpulse develops AI infrastructure for health research and consumer health products, pairing purpose-built imaging hardware with machine-learning models that analyze the captured data. Its stated pipeline has three stages: sensors capture hair, skin, dental and eye data at what the company describes as research-grade resolution, either at home or in a clinic; Genpulse models analyze the imaging data in real time; and results are delivered through consumer apps, practitioner dashboards, or third-party products via an SDK and API.

The product line spans five named offerings across six or more health domains. Lushair (lushair.ai) provides high-magnification scalp imaging with AI analysis of hair density, follicle health and skin sensitivity across nine independently assessed scalp zones, using annotation overlays (polygons for hair types, strokes for follicles, semi-transparent fills for pathology such as eczema, scalp redness, oil, scurf, follicle keratin and scalp wrinkles) under a "Genpulse Vision v2.0" annotation color specification. Glamskin (glamskin.ai) performs multi-spectrum skin analysis, mapping acne, blackheads, pores and wrinkles as stroke-only overlays and pigment, sensitivity, oil blockage and uneven tone as filled regions, with a stated three-second read and longitudinal treatment tracking. Dental AI, Eye AI and Gyn AI are listed as coming soon, covering oral health signals and plaque/gum tracking, optical health imaging for early signal mapping including pressure anomalies, and privacy-first women's wellness imaging with encrypted data and longitudinal tracking respectively.

Alongside consumer apps, Genpulse markets enterprise white-label deployment of its diagnostics under customer brands, with solution pages for dermatology, dental, ophthalmology and women's health, and states HIPAA-compliant infrastructure. A developer portal (developers.gen-pulse.com) offers REST APIs, SDKs for Python, Node.js, Swift and Kotlin, case studies, a partner program with revenue share, and open-access medical AI datasets including hair-scalp-10k (2.3GB), skin-lesion-classification (4.1GB), dental-xray-annotated (1.8GB), retinal-fundus-v2 (6.2GB) and womens-health-markers (890MB), each available on request. The company notes that its AI provides general health information rather than professional medical advice.

Business model

Genpulse combines consumer-facing device and app products (Lushair, Glamskin) with business-to-business offerings: white-label deployment of its medical-grade AI diagnostics for clinics and hospitals under the customer's own brand, enterprise APIs, SDKs, and access to medical AI datasets. A partner program is advertised with revenue share and support.

Traction

The website cites more than 50 million diagnostics run, five product lines, a 99.9% uptime SLA and sub-100ms per-image response time. Dataset download counters are listed for its open-access datasets: retinal-fundus-v2 (15.1k), hair-scalp-10k (12.4k), skin-lesion-classification (8.7k), dental-xray-annotated (5.2k) and womens-health-markers (3.8k). An iOS application is in beta distribution through TestFlight.

β–ΈFull profile β€” market position, technology, go-to-market, geography

Market position

Genpulse presents itself as a multi-domain health AI platform, covering six or more health domains through five product lines and offering infrastructure that other healthcare products can build on, rather than a single-condition diagnostic tool.

Stated differentiators include multi-domain coverage from a single infrastructure layer, purpose-built hardware paired with proprietary AI models, nine-zone independent scalp assessment and specification-aligned annotation overlays, sub-100ms per-image inference, longitudinal tracking of treatment progress, and availability of both white-label deployment and open-access medical AI datasets.

Technology

The stack couples purpose-built sensor hardware β€” high-magnification microscope lenses for scalp imaging, multi-spectrum skin imaging, camera and optical sensors for dental and eye analysis β€” with AI models that process imaging data in real time, with a stated response time of under 100ms per image. Annotation output follows an internal specification (Genpulse Annotation Color Spec v2 / Genpulse Vision v2.0) that renders hair types as polygons, follicles as strokes, and pathology and regions as 25% fills with 1px strokes, aligned to analysis scripts referenced as hair_spectrum_analysis.py and skin_analysis.py. Results are delivered via consumer apps, practitioner dashboards, REST APIs and SDKs, on infrastructure described as HIPAA-compliant with a 99.9% uptime SLA.

Go-to-market

Direct-to-consumer distribution through an iOS beta available via TestFlight and product-specific sites (lushair.ai, glamskin.ai); enterprise sales through a "book a call" motion for white-label deployments; and developer-led adoption via a documentation portal, SDK downloads, case studies, a Discord community and a revenue-share partner program.

Consumers using at-home analysis via iOS apps, practitioners using clinical dashboards, clinics and hospitals seeking branded white-label diagnostics across dermatology, dental, ophthalmology and women's health, and developers building healthcare applications on Genpulse APIs, SDKs and datasets.

Geography

The company positions its offering as globally available ("anywhere on Earth"); no specific offices or country operations are stated.

Compiled by commissioned research from 1 cited public sources β€” announcements, filings, and press listed under research sources below.

Key figures

latest reported
Diagnostics runJan 202650,000,000 diagnostics
Health domains coveredJan 20266 domains
Product linesJan 20265 product lines
Response time per imageJan 2026<100ms
Uptime SLAJan 202699.9%

Company-reported or press-reported figures, each dated to when it was claimed β€” not independently audited.

β–ΈResearch sources Β· 1

primary sources listed

1 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Genpulse do?
Genpulse builds AI-powered imaging devices and health AI infrastructure for consumer and clinical use across multiple body domains.
Who are Genpulse's investors?
Genpulse's investors include LongHash Ventures.